Clinical Trial Update: Pharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update for a pharmacogenomics study of etoposide in small cell lung cancer, spanning Phase 2 and Phase 3, with status active not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Etoposide (Etoposide)

Snippet

Sponsor: Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair | Conditions: Small Cell Lung Cancer | Phase 2, Phase 3 | Status: ACTIVE_NOT_RECRUITING